Loading patent…
AssigneeVirginia Commonwealth University
InventorsZvi SCHWARTZ, Barbara D. BOYAN, Kayla M. SCOTT, Joshua D. COHEN
Estimating the term…
Inflammatory processes, particularly those arising from trauma or injury to the region of a bone joint, are causative of osteoarthritis (OA). A composition comprising microRNA-122, microRNA-122 mimic, and/or an inhibitor of microRNA-451 reduces or inhibits inflammatory mediators in articular chondrocytes and related cells. When administered to a subject at risk of developing OA, development of OA and/or progression of OA disease are inhibited, and cartilaginous structures are preserved in the joint. Since joint injury is associated with subsequent development of OA, the treatment is particularly suitable following an acute injury to a joint.
A pharmaceutical composition for use as an inhibitor of osteoarthritis, comprising at least one agent selected from the group consisting of a microRNA-122 (miR-122), a miR-122 mimic and an inhibitor of a microRNA-451 (miR-451), wherein an inflammatory response is inhibited in articular chondrocytes.
A method of treating or inhibiting osteoarthritis in a subject in need thereof, comprising the step of administering a therapeutically sufficient amount of a pharmaceutical composition comprising at least one agent selected from the group consisting of a microRNA-122 (miR-122), a miR-122 mimic and an inhibitor of microRNA-451 (miR-451).
Dependencies are inferred from the claim text.